Details of the Drug

General Information of Drug (ID: DMJV2EK)

Drug Name
Dasatinib
Synonyms
Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
Indication
Disease Entry ICD 11 Status REF
Chronic myelogenous leukaemia 2A20.0 Approved [1], [2], [3], [4]
Multiple myeloma 2A83 Phase 2 [1], [5]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 488
Topological Polar Surface Area (xlogp) 3.6
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Elimination
0.1% of drug is excreted from urine in the unchanged form [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.8546 micromolar/kg/day [7]
Chemical Identifiers
Formula
C22H26ClN7O2S
IUPAC Name
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
Canonical SMILES
CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
InChI
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
InChIKey
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3062316
ChEBI ID
CHEBI:49375
CAS Number
302962-49-8
DrugBank ID
DB01254
TTD ID
D0E6XR
VARIDT ID
DR00182
INTEDE ID
DR0423
ACDINA ID
D00171

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [8], [9], [10]
Fyn tyrosine protein kinase (FYN) TT2B9KF FYN_HUMAN Inhibitor [8], [9], [10]
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [8], [9], [10]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [8], [9], [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [12]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [14]
Dimethylaniline oxidase 3 (FMO3) DEP76YL FMO3_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bone marrow
The Studied Disease Multiple myeloma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
LCK tyrosine protein kinase (LCK) DTT LCK 4.46E-02 -0.13 -1.09
Proto-oncogene c-Src (SRC) DTT SRC 7.46E-03 -0.2 -1.24
Fyn tyrosine protein kinase (FYN) DTT FYN 2.29E-01 -0.1 -0.51
P-glycoprotein 1 (ABCB1) DTP P-GP 7.42E-01 -4.36E-02 -2.21E-01
P-glycoprotein 1 (ABCB1) DTP P-GP 6.80E-01 2.46E-01 2.41E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 3.08E-02 -4.06E-01 -8.83E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 7.10E-01 5.87E-03 1.61E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 2.19E-02 4.44E-02 4.09E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 6.12E-01 1.16E-01 7.74E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 1.50E-04 1.94E-01 2.06E+00
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 6.86E-01 3.72E-02 2.86E-01
Dimethylaniline oxidase 3 (FMO3) DME FMO3 9.88E-01 5.88E-02 6.73E-01
Dimethylaniline oxidase 3 (FMO3) DME FMO3 1.19E-07 1.93E-01 1.92E+00
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 4.57E-01 -2.61E-02 -1.37E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 1.91E-02 -2.13E-01 -9.08E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 2.26E-02 7.10E-02 1.00E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 7.23E-01 -2.28E-02 -3.11E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.51E-01 8.39E-02 5.00E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.93E-04 -6.16E-01 -2.64E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dasatinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Dasatinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [103]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Dasatinib and Nilotinib. Myeloproliferative neoplasm [2A20] [104]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Dasatinib and Ruxolitinib. Myeloproliferative neoplasm [2A20] [103]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Dasatinib and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [105]
Coadministration of a Drug Treating the Disease Different from Dasatinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Dasatinib due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [103]
Metreleptin DM1NOEK Moderate Increased metabolism of Dasatinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [106]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Dasatinib and Ivosidenib. Acute myeloid leukaemia [2A60] [107]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Midostaurin. Acute myeloid leukaemia [2A60] [103]
Arn-509 DMT81LZ Major Increased metabolism of Dasatinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [106]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Gilteritinib. Acute myeloid leukaemia [2A60] [108]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Oliceridine. Acute pain [MG31] [103]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Dasatinib and Ivabradine. Angina pectoris [BA40] [109]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Dasatinib and Dronedarone. Angina pectoris [BA40] [104]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Dasatinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [110]
Posaconazole DMUL5EW Major Decreased metabolism of Dasatinib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [106]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Levalbuterol. Asthma [CA23] [111]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Dasatinib and Roflumilast. Asthma [CA23] [109]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [109]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Dasatinib caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [106]
Troleandomycin DMUZNIG Major Decreased metabolism of Dasatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [106]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Retigabine. Behcet disease [4A62] [103]
Cariprazine DMJYDVK Moderate Decreased metabolism of Dasatinib caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [109]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Dasatinib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [106]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Eribulin. Breast cancer [2C60-2C6Y] [104]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Dasatinib caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [112]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Lapatinib. Breast cancer [2C60-2C6Y] [103]
LY2835219 DM93VBZ Moderate Decreased metabolism of Dasatinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [113]
Tucatinib DMBESUA Major Decreased metabolism of Dasatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [106]
Palbociclib DMD7L94 Moderate Decreased metabolism of Dasatinib caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [109]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Dasatinib caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [103]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Dasatinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [103]
Bosutinib DMTI8YE Moderate Decreased metabolism of Dasatinib caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [109]
Trastuzumab Emtansine DMU1LXS Major Increased risk of bleeding by the combination of Dasatinib and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [106]
Macitentan DMP79A1 Moderate Decreased metabolism of Dasatinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [114]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [115]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [116]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [111]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Indacaterol. Chronic obstructive pulmonary disease [CA22] [116]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Arformoterol. Chronic obstructive pulmonary disease [CA22] [116]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Dasatinib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [106]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Dasatinib and Regorafenib. Colorectal cancer [2B91] [103]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Probucol. Coronary atherosclerosis [BA80] [103]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Dasatinib and Ardeparin. Coronary thrombosis [BA43] [103]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Dasatinib and Pasireotide. Cushing syndrome [5A70] [104]
Lumacaftor DMCLWDJ Major Increased metabolism of Dasatinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [106]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Dasatinib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [117]
MK-8228 DMOB58Q Moderate Decreased metabolism of Dasatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [103]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Dasatinib and Danaparoid. Deep vein thrombosis [BD71] [103]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Dasatinib and Rivaroxaban. Deep vein thrombosis [BD71] [103]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Dasatinib and Vilazodone. Depression [6A70-6A7Z] [118]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Dasatinib and Vortioxetine. Depression [6A70-6A7Z] [118]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Dasatinib and Milnacipran. Depression [6A70-6A7Z] [118]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Dasatinib and Desvenlafaxine. Depression [6A70-6A7Z] [118]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Dasatinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [119]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Dasatinib and Heme. Discovery agent [N.A.] [120]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Dasatinib caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [106]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Dasatinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [103]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Dasatinib and Apigenin. Discovery agent [N.A.] [121]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [104]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Ingrezza. Dystonic disorder [8A02] [122]
Cenobamate DMGOVHA Moderate Increased metabolism of Dasatinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [106]
Fosphenytoin DMOX3LB Major Increased metabolism of Dasatinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [106]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Dasatinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [106]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Dasatinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [123]
Tazemetostat DMWP1BH Moderate Decreased metabolism of Dasatinib caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [124]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Solifenacin. Functional bladder disorder [GC50] [103]
Mirabegron DMS1GYT Minor Decreased metabolism of Dasatinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [125]
Dexlansoprazole DM1DBV5 Major Decreased absorption of Dasatinib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [103]
Ripretinib DM958QB Moderate Decreased metabolism of Dasatinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [106]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Sunitinib. Gastrointestinal stromal tumour [2B5B] [103]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Dasatinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [103]
Colchicine DM2POTE Moderate Decreased metabolism of Dasatinib caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [103]
Boceprevir DMBSHMF Major Decreased metabolism of Dasatinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [103]
Telaprevir DMMRV29 Major Decreased metabolism of Dasatinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [106]
MK-1439 DM215WE Minor Decreased metabolism of Dasatinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [126]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Dasatinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [127]
Cobicistat DM6L4H2 Major Decreased metabolism of Dasatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Dolutegravir DMCZGRE Minor Decreased metabolism of Dasatinib caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [128]
Etravirine DMGV8QU Moderate Increased metabolism of Dasatinib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [129]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [103]
Darunavir DMN3GCH Major Decreased metabolism of Dasatinib caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Maraviroc DMTL94F Moderate Decreased clearance of Dasatinib due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [130]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Dasatinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [131]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Dasatinib caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [132]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Dasatinib due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [109]
Retapamulin DM9JXB7 Minor Decreased metabolism of Dasatinib caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [133]
Lesinurad DMUR64T Moderate Increased metabolism of Dasatinib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [106]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Dasatinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [103]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Dasatinib caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [106]
Amobarbital DM0GQ8N Moderate Increased metabolism of Dasatinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [106]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [109]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Phenolphthalein. Irritable bowel syndrome [DD91] [104]
Naloxegol DML0B41 Minor Decreased metabolism of Dasatinib caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [134]
Pemigatinib DM819JF Moderate Decreased metabolism of Dasatinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [109]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Dasatinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [106]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Dasatinib and Denosumab. Low bone mass disorder [FB83] [135]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Dasatinib and Crizotinib. Lung cancer [2C25] [136]
Brigatinib DM7W94S Moderate Increased metabolism of Dasatinib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [106]
Ceritinib DMB920Z Major Decreased metabolism of Dasatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [106]
PF-06463922 DMKM7EW Moderate Increased metabolism of Dasatinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [106]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Dasatinib and Osimertinib. Lung cancer [2C25] [137]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Dasatinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [138]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Dasatinib and Selpercatinib. Lung cancer [2C25] [109]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Dasatinib and Hydroxychloroquine. Malaria [1F40-1F45] [139]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [109]
Idelalisib DM602WT Major Decreased metabolism of Dasatinib caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [106]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Dasatinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [106]
IPI-145 DMWA24P Moderate Decreased metabolism of Dasatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [103]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Dasatinib and Acalabrutinib. Mature B-cell lymphoma [2A85] [103]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Dasatinib and Ibrutinib. Mature B-cell lymphoma [2A85] [103]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Dasatinib and Ponatinib. Mature B-cell lymphoma [2A85] [103]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Dasatinib and Arry-162. Melanoma [2C30] [103]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Dasatinib and Vemurafenib. Melanoma [2C30] [104]
Selumetinib DMC7W6R Moderate Decreased metabolism of Dasatinib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [140]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and LGX818. Melanoma [2C30] [141]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Dasatinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [109]
Danazol DML8KTN Moderate Decreased metabolism of Dasatinib caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [103]
Flibanserin DM70DTN Moderate Decreased metabolism of Dasatinib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [142]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Dasatinib and Panobinostat. Multiple myeloma [2A83] [143]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Dasatinib and Tecfidera. Multiple sclerosis [8A40] [144]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Dasatinib and Siponimod. Multiple sclerosis [8A40] [106]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Dasatinib and Fingolimod. Multiple sclerosis [8A40] [145]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Dasatinib and Ozanimod. Multiple sclerosis [8A40] [109]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Romidepsin. Mycosis fungoides [2B01] [103]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Dasatinib and Prasugrel. Myocardial infarction [BA41-BA43] [103]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Entrectinib. Non-small cell lung cancer [2C25] [106]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Lofexidine. Opioid use disorder [6C43] [104]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Dasatinib and Nepafenac. Osteoarthritis [FA00-FA05] [146]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Rucaparib. Ovarian cancer [2C73] [103]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Triclabendazole. Parasitic worm infestation [1F90] [103]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Pimavanserin. Parkinsonism [8A00] [147]
Abametapir DM2RX0I Moderate Decreased metabolism of Dasatinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [148]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Dasatinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [149]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Dasatinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [106]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Degarelix. Prostate cancer [2C82] [109]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Dasatinib and ABIRATERONE. Prostate cancer [2C82] [109]
Enzalutamide DMGL19D Major Increased metabolism of Dasatinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [106]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Relugolix. Prostate cancer [2C82] [109]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Levomepromazine. Psychotic disorder [6A20-6A25] [103]
Everolimus DM8X2EH Moderate Decreased metabolism of Dasatinib caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [150]
Axitinib DMGVH6N Moderate Decreased metabolism of Dasatinib caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [109]
Temsirolimus DMS104F Moderate Decreased metabolism of Dasatinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [151]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Dasatinib and Canakinumab. Rheumatoid arthritis [FA20] [152]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Dasatinib and Rilonacept. Rheumatoid arthritis [FA20] [152]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Dasatinib and Golimumab. Rheumatoid arthritis [FA20] [153]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Dasatinib and Iloperidone. Schizophrenia [6A20] [104]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Paliperidone. Schizophrenia [6A20] [103]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Dasatinib and Amisulpride. Schizophrenia [6A20] [154]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Asenapine. Schizophrenia [6A20] [104]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Dasatinib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [155]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Dasatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [103]
LDE225 DMM9F25 Moderate Decreased metabolism of Dasatinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [156]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Dasatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [106]
Larotrectinib DM26CQR Moderate Decreased metabolism of Dasatinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [106]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Dasatinib caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [109]
Armodafinil DMGB035 Moderate Increased metabolism of Dasatinib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [106]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Dasatinib and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [104]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [109]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Pitolisant. Somnolence [MG42] [106]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [103]
Plicamycin DM7C8YV Major Increased risk of bleeding by the combination of Dasatinib and Plicamycin. Testicular cancer [2C80] [103]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Dasatinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [157]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Dasatinib and Apixaban. Thrombosis [DB61-GB90] [103]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Dasatinib and Cangrelor. Thrombosis [DB61-GB90] [103]
Brilinta DMBR01X Major Increased risk of bleeding by the combination of Dasatinib and Brilinta. Thrombosis [DB61-GB90] [103]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Lenvatinib. Thyroid cancer [2D10] [103]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Dasatinib and Cabozantinib. Thyroid cancer [2D10] [109]
Saxagliptin DMGXENV Moderate Decreased metabolism of Dasatinib caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [109]
Elagolix DMB2C0E Moderate Increased metabolism of Dasatinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [106]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Dasatinib and Betrixaban. Venous thromboembolism [BD72] [103]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Dasatinib and Valganciclovir. Virus infection [1A24-1D9Z] [106]
⏷ Show the Full List of 168 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dasatinib 100 mg tablet 100 mg Oral Tablet Oral
Dasatinib 140 mg tablet 140 mg Oral Tablet Oral
Dasatinib 20 mg tablet 20 mg Oral Tablet Oral
Dasatinib 50 mg tablet 50 mg Oral Tablet Oral
Dasatinib 70 mg tablet 70 mg Oral Tablet Oral
Dasatinib 80 mg tablet 80 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5678).
2 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
3 Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007 Nov;29(11):2289-308.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
6 BDDCS applied to over 900 drugs
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9 In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. J Clin Pharmacol. 2008 Oct;48(10):1179-88.
10 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
11 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
12 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
13 Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80.
14 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
15 Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
26 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
27 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
28 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
29 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
30 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
31 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
32 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
33 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
34 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
35 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
36 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
37 Drug Interactions Flockhart Table
38 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
39 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
40 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
41 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
42 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
43 Physiologically based pharmacokinetic modeling approach to predict drug-drug interactions with ethionamide involving impact of genetic polymorphism on FMO3. J Clin Pharmacol. 2019 Jun;59(6):880-889.
44 Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
45 FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
46 Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
47 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
48 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
49 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
50 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
51 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
52 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
53 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
54 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
55 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
56 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
57 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
58 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
59 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
60 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
61 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
62 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
63 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
64 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
65 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
66 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
67 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
68 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
69 FDA Drug Development and Drug Interactions
70 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
71 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
72 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
73 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
74 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
75 National Cancer Institute Drug Dictionary (drug id 596693).
76 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
77 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
78 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
79 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
80 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
81 National Cancer Institute Drug Dictionary (drug id 596693).
82 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
83 Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
84 Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
85 (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
86 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
87 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
88 Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
89 ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
90 Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
91 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
92 Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
93 Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
94 NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88.
95 Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15;99(2):664-71.
96 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
97 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
98 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
99 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
100 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
101 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
102 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
103 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
104 Canadian Pharmacists Association.
105 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
106 Cerner Multum, Inc. "Australian Product Information.".
107 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
108 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
109 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
110 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
111 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
112 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
113 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
114 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
115 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
116 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
117 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
118 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
119 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
120 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
121 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
122 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
123 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
124 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
125 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
126 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
127 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
128 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
129 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
130 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
131 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
132 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
133 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
134 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
135 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
136 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
137 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
138 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
139 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
140 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
141 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
142 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
143 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
144 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
145 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
146 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
147 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
148 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
149 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
150 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
151 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
152 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
153 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
154 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
155 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
156 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
157 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.